Richard Kim1, Federico Aucejo. 1. Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, USA. Richard.kim@moffitt.org
Abstract
BACKGROUND: No standard therapies have been established for the treatment of recurrent hepatocellular carcinoma (HCC) after liver transplantation. DISCUSSION: Sirolimus is a mTOR inhibitor which has been used as an immunosuppressive medication in patients who are at high risk of tumor reoccurrence after liver transplantation. Sorafenib is a multikinase inhibitor approved for the treatment of advanced HCC. However the role of sorafenib in patients with HCC reoccurrence after liver transplantation is unclear. RESULTS: Combination of sirolimus and sorafenib appears to have synergistic effect when treating HCC in preclinical settings. We report a case of a post-liver transplant patient treated with sorafenib and sirolimus for hepatic HCC recurrence who exhibited complete radiologic response after 5A months of therapy.
BACKGROUND: No standard therapies have been established for the treatment of recurrent hepatocellular carcinoma (HCC) after liver transplantation. DISCUSSION: Sirolimus is a mTOR inhibitor which has been used as an immunosuppressive medication in patients who are at high risk of tumor reoccurrence after liver transplantation. Sorafenib is a multikinase inhibitor approved for the treatment of advanced HCC. However the role of sorafenib in patients with HCC reoccurrence after liver transplantation is unclear. RESULTS: Combination of sirolimus and sorafenib appears to have synergistic effect when treating HCC in preclinical settings. We report a case of a post-liver transplant patient treated with sorafenib and sirolimus for hepatic HCC recurrence who exhibited complete radiologic response after 5A months of therapy.
Authors: John D Hainsworth; David R Spigel; Howard A Burris; David Waterhouse; Bobby L Clark; Robert Whorf Journal: J Clin Oncol Date: 2010-04-05 Impact factor: 44.544
Authors: H Kirimlioglu; I Dvorchick; K Ruppert; S Finkelstein; J W Marsh; S Iwatsuki; A Bonham; B Carr; M Nalesnik; G Michalopoulos; T Starzl; J Fung; A Demetris Journal: Hepatology Date: 2001-09 Impact factor: 17.425
Authors: Pippa Newell; Sara Toffanin; Augusto Villanueva; Derek Y Chiang; Beatriz Minguez; Laia Cabellos; Radoslav Savic; Yujin Hoshida; Kiat Hon Lim; Pedro Melgar-Lesmes; Steven Yea; Judit Peix; Kemal Deniz; M Isabel Fiel; Swan Thung; Clara Alsinet; Victoria Tovar; Vincenzo Mazzaferro; Jordi Bruix; Sasan Roayaie; Myron Schwartz; Scott L Friedman; Josep M Llovet Journal: J Hepatol Date: 2009-06-12 Impact factor: 25.083
Authors: Augusto Villanueva; Derek Y Chiang; Pippa Newell; Judit Peix; Swan Thung; Clara Alsinet; Victoria Tovar; Sasan Roayaie; Beatriz Minguez; Manel Sole; Carlo Battiston; Stijn Van Laarhoven; Maria I Fiel; Analisa Di Feo; Yujin Hoshida; Steven Yea; Sara Toffanin; Alex Ramos; John A Martignetti; Vincenzo Mazzaferro; Jordi Bruix; Samuel Waxman; Myron Schwartz; Matthew Meyerson; Scott L Friedman; Josep M Llovet Journal: Gastroenterology Date: 2008-08-20 Impact factor: 22.682
Authors: Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix Journal: N Engl J Med Date: 2008-07-24 Impact factor: 91.245
Authors: Michael A Zimmerman; James F Trotter; Michael Wachs; Tom Bak; Jeffrey Campsen; Afshin Skibba; Igal Kam Journal: Liver Transpl Date: 2008-05 Impact factor: 5.799
Authors: V Mazzaferro; E Regalia; R Doci; S Andreola; A Pulvirenti; F Bozzetti; F Montalto; M Ammatuna; A Morabito; L Gennari Journal: N Engl J Med Date: 1996-03-14 Impact factor: 176.079